Our first decade of innovation in precision medicine

April 21, 2021 by Fouad Namouni

This month marks 10 years since Blueprint Medicines began operations, and it’s a natural time to celebrate the science, patients and people who have made…

Read more

Joining Other Precision Medicine Stakeholders to Develop United Language for Testing

June 11, 2020 by Elissa Quinn, Associate Director, Precision Medicine

With more biomarker-targeted therapies becoming available, patient advocacy groups have increasingly talked about the challenge of confusing terminology for cancer testing. In March 2019, my…

Read more

ASCO 2019: Advancing Cancer Treatment with Precision Therapies

May 31, 2019

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, a key focus will be precision therapy – targeting genetic drivers of cancer with…

Read more

Blueprint Medicines Recognizes International FOP Awareness Day

April 23, 2019

Letter from Marion Dorsch, Chief Scientific Officer Today, Blueprint Medicines stands with the patient community and recognizes International Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day. In…

Read more

How Our Research Platform Helped Accelerate the Discovery of BLU-667

April 10, 2019 by Jason Brubaker

Discovering potent and selective kinase drugs is a challenging endeavor. Setting up and completing a screen of a new drug target against a compound library…

Read more

Blueprint Medicines Introduces The Lens

January 2, 2019 by Marion Dorsch, Chief Scientific Officer

Welcome to The Lens, our new thought leadership platform to share our team’s expertise in precision medicine. We are pioneers in this rapidly evolving field,…

Read more